Last reviewed · How we verify
Exploratory Study of a Digital Therapeutics in People With Schizophrenia
CT-155 is a novel prescription digital therapeutic (PDT) being developed by Click Therapeutics, Inc. (Click) and Boehringer Ingelheim (BI) using an interactive, software-based intervention to treat schizophrenia
Details
| Lead sponsor | Click Therapeutics, Inc. |
|---|---|
| Phase | NA |
| Status | COMPLETED |
| Enrolment | 48 |
| Start date | Thu Mar 31 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sun Jul 31 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Schizophrenia
Interventions
- Clinical Learning Study smartphone app (i.e., the study app)
Countries
United States